Inclusion Criteria:~1. Diagnosis of probable Alzheimer disease according to National Institute on
Aging-Alzheimer's Association (NIA-AA) criteria~2. Male or female age 50 to 86 years~3. MMSE between 12-26~4.
Total bilirubin less than or equal to 1.5mg/dL~5. Alanine aminotransferase level (ALT) and aspartate
aminotransferase (AST) less than or equal to two times normal,~6. Albumin greater than or equal to 3.0mg/dL~7.
Serum creatinine less than or equal to 1.5 mg/dL~8. White Blood Count (WBC) >3,500/mm3; platelets >100,000/mm3;
hematocrit (HCT) >32%.~9. INR<1.4 If on medications affecting cognition (rivastigmine, galantamine, donepezil,
memantine), participants must be on stable dosage for at least 4 weeks prior to screening and should remain at
a stable dosage during the course of the study.~10. English language speaking~11. Formal education of eight or
more years~12. Stable pharmacological treatment of any other chronic conditions for at least 30 days prior to
screening~
